معرفی
Lara Graham is a Research Fellow at the University of Southampton specializing in cancer immunology with a focus on natural killer (NK) cell biology. Her work investigates NK cell mechanisms in anti-tumor immunity, particularly regarding hematological malignancies and solid tumors, through translational research targeting immune checkpoints and enhancing NK cell function for improved cancer therapies.
Her research spans cancer immunology, NK cell biology, and immunotherapy, with emphasis on molecular mechanisms of NK cell activation via KIR receptors and the NKG2A:HLA-E checkpoint axis. She explores therapeutic strategies including XPO1 inhibition to sensitize cancer cells to NK-mediated killing and develops antibody-based approaches to overcome tumor immune evasion, contributing significantly to immuno-oncology advancements.
Analysis of her 2022-2024 publications reveals a strong translational focus, with key themes including CAR-NK engineering, antibody-dependent cellular cytotoxicity enhancement, and disruption of immune checkpoints. Her work demonstrates consistent innovation in leveraging NK cell biology for clinical applications, particularly in chronic lymphocytic leukemia and solid tumor contexts.
No scientific awards were documented in the provided materials.
While no explicit details about student advising or research grants were available, her collaborative publication pattern suggests active mentorship within research teams focused on immunotherapy development.
Graham operates within interdisciplinary research networks at the University of Southampton, collaborating extensively with immunologists, oncologists, and hematologists including Matthew D. Blunt and Salim I. Khakoo. Her work appears anchored in translational cancer research teams investigating NK cell-based therapies, particularly for hematological malignancies and immune checkpoint modulation.
